Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.44 |
| ▸ | CSNK1E | P49674 | 4/20 | 0.41 |
| ▸ | CDK4 | P11802 | 10/20 | 0.40 |
| ▸ | CDK6 | Q00534 | 3/20 | 0.40 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.37 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.37 |
| ▸ | BPTF | Q12830 | 1/20 | 0.37 |
| ▸ | LATS1 | O95835 | 1/20 | 0.37 |
| ▸ | EIF2AK4 | Q9P2K8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18291260 | 0.82 | HRH4 (0.38) | HDAC1PRKCQCDK4BPTF | |
| SCHEMBL3723054 | 0.75 | BPTF (0.62) | BPTF | |
| SCHEMBL13769162 | 0.75 | CDK4 (0.44) | HDAC1PRKCQCDK4CDK6 | |
| Hydrochloric Acid SCHEMBL21274572 | 0.74 | BPTF (0.61) | BPTF | |
| SCHEMBL18290954 | 0.71 | PTPN11 (0.45) | — | |
| SCHEMBL16580827 | 0.71 | MAPT (0.46) | HDAC1PRKCQLATS1 | |
| SCHEMBL18291245 | 0.71 | HRH3 (0.38) | BPTF | |
| SCHEMBL18096405 | 0.71 | PLD1 (0.58) | HDAC1PRKCQCSNK1E | |
| SCHEMBL30426817 | 0.71 | HDAC1 (0.45) | HDAC1PRKCQCSNK1ECDK4CDK6 | |
| Hydrochloric Acid SCHEMBL23124046 | 0.70 | PLD1 (0.57) | HDAC1PRKCQCSNK1E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009085185-A1 | FUSED PYRIDINE, PYRIMIDINE AND TRIAZINE COMPOUNDS AS CELL CYCLE INHIBITORS | AMGEN INC. (US) | 2009-07-09 | — | — | WO | disclosed |